Elbonix (Eltrombopag 25mg)

1. What is Eltrombopag?

Elbonix (Eltrombopag) is a generic thrombopoietin receptor agonist for chronic immune (idiopathic) thrombocytopenia (ITP).

2. Eltrombopa cost 

The generic eltrombopag price in india is only 2% now compare to the previous

Eltrombopa is a thrombopoietin receptor agonist indicated for the treatment of:

(1).  thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Elbonix should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.

(2).  thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Elbonix should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy.

(3).  patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.

3. Limitations of Use:

(1).  Elbonix is not indicated for the treatment of patients with myelodysplastic syndrome (MDS).

(2).  Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection.

4. Eltrombopa Dosing

(1).  Take on an empty stomach (1 hour before or 2 hours after a meal).

(2).  Chronic ITP: Initiate Elbonix at 50 mg once daily for most adult and pediatric patients 6 years and older and at 25 mg once daily for pediatric patients aged 1 to 5 years. Dose reductions are needed for patients with hepatic impairment and some patients of East Asian ancestry. Adjust to maintain platelet count greater than or equal to 50 x 109/L. Do not exceed 75 mg per day.

(3). Chronic Hepatitis C-associated Thrombocytopenia: Initiate Elbonix at 25 mg once daily for all patients. Adjust to achieve target platelet count required to initiate antiviral therapy. Do not exceed a daily dose of 100 mg.

(4). Severe Aplastic Anemia: Initiate Elbonix at 50 mg once daily for most patients. Reduce initial dose in patients with hepatic impairment or patients of East Asian ancestry. Adjust to maintain platelet count greater than 50 x 109/L. Do not exceed 150 mg per day.

5. Eltrombopa side effects

Eltrombopa can cause serious side effects, including:

Liver problems. If you have chronic hepatitis C virus, and take Eltrombopa with interferon and ribavirin treatment, Eltrombopa may increase your risk of liver problems. Tell your healthcare provider right away if you have any of these signs and symptoms of liver problems:

• yellowing of the skin or the whites of the eyes (jaundice)
• unusual darkening of the urine
• unusual tiredness
• right upper stomach area (abdomen) pain · confusion · swelling of the stomach area (abdomen)

It is not known if Eltrombopa is safe and effective when used with other antiviral medicines that are approved to treat chronic hepatitis C. It is not known if Eltrombopa is safe and effective in children with chronic hepatitis C or severe aplastic anemia or in children younger than 1 year with ITP.

6. Eltrombopa Pi

For more Prescribing information，please check the → “FDA Prescribing Information”.